【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。

Trazodone is used primarily in the treatment of mental depression or depression/anxiety disorder

Trazodone may be safely combined with MAOIs for refractory depression. Disadvantages of trazodone include a high incidence of priapism, orthostatic hypotension, and induction or exacerbation of atrial and ventricular arrhythmias. However, compared with the TCAs, trazodone is still considered less cardiotoxic.

Trazodone is rapidly and almost completely absorbed from the GI tract following oral administration. Trazodone is extensively metabolized in the liver via hydroxylation, oxidation, N-oxidation, and splitting of the pyridine ring. Approximately 70–75% of an oral dose of trazodone is excreted in urine within 72 hours of administration, principally as metabolites. The half-life of trazodone in the initial phase (t?α) is about 3–6 hours and the half-life in the terminal phase (t?β) is about 5–9 hours.

1) Hypersensitivity to trazodone 2) Carcinoid syndrome 3) Trazodone is not recommended for use during initial recovery phase of myocardial infarction.

C

Because trazodone is distributed into milk, the drug should be used with caution in nursing women.

Trazodone has a low incidence of anticholinergic effects and cardiovascular effects. Adverse effects include ventricular arrhythmias, hypotension, heart block, drowsinness, weight gain, blurred vision, dizziness, and priapism.

50-600mg daily, usually response range between 100-300mg daily in single or divided dose.